Enable JavaScript to ensure website accessibility
Precipio Identifies Manufacturer For Its IV-Cell Media

Manufacturing Partner enables Precipio to address customer demand and plans for global distribution NEW HAVEN, [...]

Precipio’s HemeScreen™ Adopted By Methodist Health

New Molecular Screening Assay Technology Gains Traction NEW HAVEN, CT, (April 3, 2019) – Specialty diagnostics [...]

Precipio CEO Issues Shareholder Update Letter

NEW HAVEN, CT, (March 11th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), issues the following [...]

Precipio Provides Corporate Update Shareholder Call

Conference Call to be held Thursday February 21st, 2019 at 4:30pm Eastern Time NEW HAVEN, [...]

Precipio 2018 Revenues Increase 66% Over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability

Shareholder call scheduled for February 21st at 4:30PM EST NEW HAVEN, CT, (February 14th, 2019) – [...]

Makati Medical Center In The Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology For Liquid Biopsies

One of Nation’s Premier Hospitals to Become Central Laboratory for Liquid Biopsies NEW HAVEN, CT, [...]

Precipio Announces First US Government Customer For ICE COLD-PCR™ Mutation Enrichment Technology

Department of Defense Approves Precipio as a Vendor for its Liquid Biopsy Testing NEW HAVEN, [...]

Precipio Files Patent For HemeScreen™, Its Novel Molecular Assay

Commercialization of assay underway with both in-house testing and hospital sales NEW HAVEN, CT, (January [...]

Precipio Reports Strong Mid-Quarter Growth

Key Metrics Indicate Continued Growth QoQ for Fourth Quarter 2018 NEW HAVEN, CT, (December 12th, [...]

Precipio Announces $1.2 Million Securities Purchase Agreement With Participation From Members Of Its Board Of Directors, And Other Investors

NEW HAVEN, CT, (December 4th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...]